Logo

Danaher Completes Acquisition of Cepheid

Nov 07, 2016

NEW YORK (GenomeWeb) ­– Danaher announced Friday that it has completed its $4 billion acquisition of Cepheid.

Cepheid has been merged into Copper Merger Sub, a wholly owned subsidiary of Danaher, resulting in Cepheid becoming an indirect wholly owned subsidiary of Danaher.

Each outstanding share of Cepheid common stock was cancelled — except for shares held by Danaher, Copper Merger Sub, Cepheid, and respective subsidiaries — and converted into $53.00 per share in cash.

Cepheid's common stock will no longer be traded on the Nasdaq.

Danaher's shares rose nearly 2 percent to $78.30 in morning trading on the New York Stock Exchange.

Filed under

Infectious Disease
PCR
Molecular Diagnostics
mergers & acquisitions
Cepheid
Danaher
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.